CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
November 20, 2025
Isatuximab for relapsed AL amyloidosis Free
CME
Blood (2025) 146 (21): 2615.
Connected Content
A related article has been published:
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)
Citation
Isatuximab for relapsed AL amyloidosis. Blood 2025; 146 (21): 2615. doi: https://doi.org/10.1182/blood.2025031732
Download citation file: